Genmab | GEN - Koszty Sprzedaży I Administracji





Koszty Sprzedaży I Administracji Zmiana Data
Agios Pharmaceuticals USD 38.46M 4.51M 2026-03
Amarin USD 18.97M 1.03M 2025-12
Amgen USD 1.72B 134M 2026-06
argenx SE USD 598M 181M 2026-09
AstraZeneca USD 4.07B 1.73B 2026-09
Bayer EUR 3.96B 267M 2026-06
BioMarin Pharmaceutical USD 395.55M 137.27M 2026-06
Demant DKK 7.09B 1B 2026-06
Exelixis USD 154.56M 6.93M 2026-09
Fresenius Medical Care EUR 736.01M 12.99M 2026-06
Genmab DKK 205M 39M 2026-06
GlaxoSmithKline GBP 2.16B 39M 2026-09
GN Store Nord DKK 805M 42M 2026-06
GRIFOLS EUR 289M 8M 2026-06
Hikma Pharmaceutical USD 288M 149M 2025-12
Insmed USD 253.03M 5.56M 2026-09
Lakefront Biotherapeutics EUR 22.5M 13M 2026-06
Merck EUR 1.57B 49M 2026-06
Novartis USD 3.08B 163M 2026-09
Regeneron Pharmaceuticals USD 662.1M 14.4M 2026-06
Roche Holding CHF 6.37B 908M 2026-06
Sanofi EUR 2.63B 307M 2026-06
UCB EUR 1.47B 193M 2025-12